MARKET

SPRO

SPRO

CBOE S&P500 Bufr Prtct Indx Blnc Series
CBOE

Real-time Quotes | Nasdaq Global Index Data Service

3,049.05
+8.94
+0.29%
Opening 09:30 08/18 EDT
OPEN
--
PREV CLOSE
3,040.11
HIGH
--
LOW
--
52 WEEK HIGH
3,098.74
52 WEEK LOW
2,704.94
VOLUME
--
% RANGE
--
1D
5D
1M
3M
1Y
5Y
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 1.14% and 13.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/10 21:25
Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Spero Therapeutics press release (<span class="tick...
Seekingalpha · 08/10 20:50
-- Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q2 Revenue $2M
-- Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q2 Revenue $2M
MT Newswires · 08/10 16:25
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial...
GlobeNewswire · 08/09 12:05
The Women Who Shaped Short-Term Rental History
The dudes got all the headlines and — let’s face it — because of ingrained sexism and the traditional old boys’ networks, they took an inordinate share of the top jobs, but there were many talented women leaders and entrepreneurs who likewise shaped the hi...
Skift · 07/06 06:30
Spero Therapeutics' Shares Plunge As FDA Issued Refusal Letter For Urinary Tract Infection Candidate
The U.S.
Benzinga · 06/27 20:48
UPDATE 1-U.S. FDA declines to approve Spero's urinary tract infection drug
The U.S. Food and Drug Administration (FDA) declined to approve Spero Therapeutics Inc's oral antibiotic drug for the treatment of patients with complicated urinary tract infections, the company said on Monday. In the complete response letter, the health ...
Reuters · 06/27 20:27
FDA rejects Spero's application seeking approval of its urinary tract infection tablets
Spero Therapeutics (NASDAQ:SPRO) on Monday said the U.S. FDA had rejected its new drug application seeking approval for its tebipenem HBr oral tablets for the treatment of complicated urinary tract
Seekingalpha · 06/27 20:13
More
No Data
Learn about the latest financial forecast of SPRO. Analyze the recent business situations of CBOE S&P500 Bufr Prtct Indx Blnc Series through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data